Current strategies for ischemic stroke prevention: role of multimodal combination therapies
- PMID: 17934879
- DOI: 10.1007/s00415-007-0569-9
Current strategies for ischemic stroke prevention: role of multimodal combination therapies
Abstract
Stroke remains a global leading cause of death and long-term disability, highlighting the need for more effective treatment approaches. The majority of strokes are of ischemic origin, often caused by large- or small-artery atherothrombosis, or cardioembolism. Considering the systemic nature of the atherothrombotic disease process, stroke patients are at increased risk for ischemic events in several vascular territories: cerebral, coronary and peripheral. Due to the limited options for acute stroke therapies, stroke prevention is an important therapeutic approach. In addition to the management of modifiable risk factors such as hypertension, dyslipidemia and smoking through pharmacotherapy or lifestyle adjustments, anticoagulants, surgical and perhaps endovascular approaches are indicated in certain patients. Antiplatelet therapies using various agents are a cornerstone of secondary stroke prevention. To ensure the appropriate continuum of care after hospitalization for ischemic stroke, some interventions for the prevention of recurrent ischemic stroke should be initiated during the acute hospitalization setting and maintained in the out-patient setting.
Similar articles
-
New perspectives on the pharmacotherapy of ischemic stroke.J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2 Suppl 1):S46-56; quiz S56-7. doi: 10.1331/154434504322904604. J Am Pharm Assoc (2003). 2004. PMID: 15095935 Review.
-
The emergency department: first line of defense in preventing secondary stroke.Acad Emerg Med. 2006 Feb;13(2):215-22. doi: 10.1197/j.aem.2005.07.035. Epub 2006 Jan 25. Acad Emerg Med. 2006. PMID: 16436789
-
Secondary stroke prevention: from guidelines to clinical practice.J Natl Med Assoc. 2008 Oct;100(10):1125-37. doi: 10.1016/s0027-9684(15)31482-6. J Natl Med Assoc. 2008. PMID: 18942273 Review.
-
Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.Ann Med. 2010;42(1):19-35. doi: 10.3109/07853890903260898. Ann Med. 2010. PMID: 20092398 Review.
-
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.Cerebrovasc Dis. 2001;11 Suppl 1:85-95. doi: 10.1159/000049130. Cerebrovasc Dis. 2001. PMID: 11244205 Review.
Cited by
-
A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.Clin Cardiol. 2013 Jul;36(7):383-93. doi: 10.1002/clc.22137. Epub 2013 May 13. Clin Cardiol. 2013. PMID: 23670948 Free PMC article. Review.
-
Enhanced neurogenesis and cell migration following focal ischemia and peripheral stimulation in mice.Dev Neurobiol. 2008 Nov;68(13):1474-86. doi: 10.1002/dneu.20674. Dev Neurobiol. 2008. PMID: 18777565 Free PMC article.
-
Neuroprotective effects of methanolic extract from Chuanxiong Rhizoma in mice with middle cerebral artery occlusion-induced ischemic stroke: suppression of astrocyte- and microglia-related inflammatory response.BMC Complement Med Ther. 2024 Apr 4;24(1):140. doi: 10.1186/s12906-024-04454-w. BMC Complement Med Ther. 2024. PMID: 38575941 Free PMC article.
-
Therapeutic Effects of Resveratrol on Ischemia-Reperfusion Injury in the Nervous System.Neurochem Res. 2021 Dec;46(12):3085-3102. doi: 10.1007/s11064-021-03412-z. Epub 2021 Aug 7. Neurochem Res. 2021. PMID: 34365594 Review.
-
Amelioration of Brain Damage after Treatment with the Methanolic Extract of Glycyrrhizae Radix et Rhizoma in Mice.Pharmaceutics. 2022 Dec 12;14(12):2776. doi: 10.3390/pharmaceutics14122776. Pharmaceutics. 2022. PMID: 36559268 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical